The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306.
S. Stintzing
Honoraria - Merck
Other Remuneration - Merck
J. Neumann
No relevant relationships to disclose
A. Jung
No relevant relationships to disclose
L. Fischer von Weikersthal
No relevant relationships to disclose
T. Decker
No relevant relationships to disclose
U. Vehling-Kaiser
No relevant relationships to disclose
E. Jaeger
No relevant relationships to disclose
T. Heintges
No relevant relationships to disclose
C. Stoll
No relevant relationships to disclose
D. P. Modest
No relevant relationships to disclose
T. Kirchner
Honoraria - Merck
W. Scheithauer
Honoraria - Merck
Other Remuneration - Merck
V. Heinemann
Honoraria - Merck
Research Funding - Merck
Other Remuneration - Merck